STOCK TITAN

Humanigen, Inc. - HGEN STOCK NEWS

Welcome to our dedicated page for Humanigen news (Ticker: HGEN), a resource for investors and traders seeking the latest updates and insights on Humanigen stock.

Humanigen, Inc. (OTC Pink: HGEN) is a clinical-stage biopharmaceutical company with a focus on developing innovative therapies to enhance patient outcomes. At the core of the company's mission is the development of lenzilumab, a first-in-class monoclonal antibody designed to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), a key cytokine involved in inflammatory responses.

The company's leading product, lenzilumab, is currently being investigated in multiple clinical trials. One of the major studies is the RATinG (Risk Adapted Therapy in Acute GvHD) trial, which aims to explore lenzilumab's efficacy in treating acute Graft versus Host Disease (aGvHD). This condition affects a significant proportion of patients who undergo allogeneic stem cell transplants, with high rates of morbidity and mortality. The Phase 2/3 study is conducted in collaboration with the UK-based IMPACT partnership and is poised to enroll patients across 18 treatment centers.

In addition to aGvHD, lenzilumab is also being tested as a treatment for chronic myelomonocytic leukemia and to mitigate toxicities associated with CAR-T therapy through investigator-initiated trials. The company's expertise in antibody development extends beyond lenzilumab, as demonstrated by the development of an antibody drug conjugate (ADC) utilizing its EphA-3 targeted monoclonal antibody ifabotuzumab for the treatment of solid tumors.

Humanigen’s pipeline is fortified by state-of-the-art antibody customization technologies designed to optimize therapeutic effects while minimizing undesired side effects. The company’s research and development efforts are supported by extensive partnerships with leading institutions such as the University of Birmingham's Cancer Research UK Clinical Trials Unit and the British Society of Blood and Marrow Transplantation.

Despite being at a pre-commercial stage, Humanigen demonstrates resilience and strategic focus, advancing its therapeutic candidates through critical clinical milestones. Financial and market challenges remain, but the company is actively exploring strategic options, including potential restructuring to maintain its innovative edge and ongoing operations.

For more detailed information, including the latest updates and news, visit www.humanigen.com and follow Humanigen on Twitter.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
clinical trial covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.13%
Tags
covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.14%
Tags
covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
covid-19
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.6%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
partnership covid-19
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.48%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.41%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.21%
Tags

FAQ

What does Humanigen, Inc. specialize in?

Humanigen, Inc. specializes in developing innovative therapies, including lenzilumab, a monoclonal antibody aimed at neutralizing GM-CSF to treat conditions such as acute Graft versus Host Disease (aGvHD).

What is lenzilumab?

Lenzilumab is a first-in-class monoclonal antibody developed by Humanigen to neutralize granulocyte-macrophage colony-stimulating factor (GM-CSF), thereby potentially improving outcomes in conditions like aGvHD.

What is the RATinG trial?

The RATinG trial is a Phase 2/3 clinical study investigating the efficacy of lenzilumab in treating high-risk acute Graft versus Host Disease (aGvHD) in patients who have undergone allogeneic stem cell transplants.

What are the key partnerships supporting Humanigen's research?

Humanigen collaborates with prestigious institutions like the University of Birmingham's Cancer Research UK Clinical Trials Unit and the British Society of Blood and Marrow Transplantation.

What other conditions is lenzilumab being investigated for?

Besides aGvHD, lenzilumab is being explored as a treatment for chronic myelomonocytic leukemia and to prevent toxicities associated with CAR-T therapy.

What is ifabotuzumab?

Ifabotuzumab is an antibody drug conjugate (ADC) targeting EphA-3, developed by Humanigen, currently being investigated for the treatment of solid tumors.

Is Humanigen a publicly traded company?

Yes, Humanigen, Inc. is publicly traded under the symbol HGEN on OTC Pink.

How can I stay updated with Humanigen's latest news?

You can stay updated by visiting their official website at www.humanigen.com and following their official Twitter account.

What challenges does Humanigen face?

Humanigen faces financial and market challenges typical of clinical-stage biopharmaceutical companies, including the need for additional capital and strategic restructuring.

What is Humanigen's approach to antibody development?

Humanigen employs advanced customization technologies to develop antibodies that enhance desired therapeutic effects while reducing potential side effects.

Humanigen, Inc.

Nasdaq:HGEN

HGEN Rankings

HGEN Stock Data

23.82k
110.48M
10.35%
0.49%
3.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Burlingame